Comparison of Outcomes of Hematopoietic Cell Transplants from T-Replete Haploidentical Donors Using Post-Transplantation Cyclophosphamide with 10 of 10 HLA-A, -B, -C, -DRB1, and -DQB1 Allele-Matched Unrelated Donors and HLA-Identical Sibling Donors: A Multivariable Analysis Including Disease Risk Index

Biology of Blood and Marrow Transplantation

Volumn 22, Issue 1, 2016, Pages 125-133

  Bashey, Asad ^a   Zhang, Xu ^b   Jackson, Katelin ^a   Brown, Stacey ^a   Ridgeway, Michelle ^a   Solh, Melhem ^a   Morris, Lawrence E ^a   Holland, H Kent ^a   Solomon, Scott R ^a  

^a NORTHSIDE HOSPITAL   (United States)

^b GEORGIA STATE UNIVERSITY   (United States)

Author keywords

Alternative donors; Haploidentical; Post transplantation cyclophosphamide; T replete

Indexed keywords

CYCLOPHOSPHAMIDE; HLA A ANTIGEN; HLA B ANTIGEN; HLA C ANTIGEN; HLA DQB1 ANTIGEN; HLA DRB1 ANTIGEN; HLA ANTIGEN;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ALLOTRANSPLANTATION; ARTICLE; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; DONOR SELECTION; FEMALE; FOLLOW UP; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; HAPLOIDY; HEALTH CARE QUALITY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA SYSTEM; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MYELOABLATIVE CONDITIONING; NEUTROPHIL COUNT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; THROMBOCYTE COUNT; UNRELATED DONORS; ADOLESCENT; AGED; CLINICAL TRIAL; DONOR; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HISTOCOMPATIBILITY TEST; MORTALITY; RISK FACTOR; SURVIVAL RATE;

ADOLESCENT; ADULT; AGED; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; SURVIVAL RATE; TISSUE DONORS;

EID: 84951761105     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2015.09.002     Document Type: Article

References (23)

1. O'Donnell P.V., Luznik L., Jones R.J., et al. Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2002, 8:377-386.
2. Luznik L., O'Donnell P.V., Symons H.J., et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2008, 14:641-650.
3. Brunstein C.G., Fuchs E.J., Carter S.L., et al. Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. Blood 2011, 118:282-288.
4. Ciurea S.O., Mulanovich V., Saliba R.M., et al. Improved early outcomes using a T cell-replete graft compared with T cell-depleted haploidentical hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2012, 18:1835-1844.
5. Bashey A., Zhang X., Sizemore C.A., et al. T cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation. J Clin Oncol 2013, 31:1310-1316.
6. Raiola A.M., Dominietto A., Ghiso A., et al. Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning. Biol Blood Marrow Transplant 2013, 19:117-122.
7. McCurdy S.R., Kanakry J.A., Showel M.M., et al. Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide. Blood 2015, 125:3024-3031.
8. Dominietto A, Raiola AM, Bruno B, et al. Rapid immune reconstitution following unmanipulated haploidentical BMT with post-transplant high-dose cyclophosphamide. American Society of Hematology abstracts. Available from . Accessed September 16, 2015. https://ash.confex.com/ash/2011/webprogram/Paper42454.html.
9. Castagna L., Crocchiolo R., Bramanti S., et al. Lower relapse and better PFS among chemosensitive patients undergoing allogeneic transplantation by haploidentical compared with HLA-identical donor: results on a cohort of 94 patients with Hodgkin's lymphoma. Blood 2013, 122:2144.
10. Raiola A.M., Dominietto A., di Grazia C., et al. Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts. Biol Blood Marrow Transplant 2014, 20:1573-1579.
11. Armand P., Gibson C.J., Cutler C., et al. A disease risk index for patients undergoing allogeneic stem cell transplantation. Blood 2012, 120:905-913.
12. Armand P., Kim H.T., Logan B.R., et al. Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. Blood 2014, 123:3664-3671.
13. Giralt S., Ballen K., Rizzo D., et al. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant 2009, 15:367-369.
14. Luger S.M., Ringdén O., Zhang M.J., et al. Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS. Bone Marrow Transplant 2012, 47:203-211.
15. Solomon S.R., Sizemore C.A., Sanacore M., et al. Haploidentical transplantation using T cell-replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematologic malignancies who lack conventional donors is well tolerated and produces excellent relapse-free survival: results of a prospective phase II trial. Biol Blood Marrow Transplant 2012, 18:1859-1866.
16. Solomon S.R., Sizemore C.A., Sanacore M., et al. Total body irradiation-based myeloablative haploidentical stem cell transplantation is a safe and effective alternative to unrelated donor transplantation in patients without matched sibling donors. Biol Blood Marrow Transplant 2015, 21:1299-1307.
17. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995, 15:825-828.
18. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease, I: Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant 2005, 11:945-956.
19. Gragert L., Eapen M., Williams E., et al. HLA match likelihoods for hematopoietic stem cell grafts in the US registry. N Engl J Med 2014, 371:339-348.
20. Saber W., Opie S., Rizzo J.D., et al. Outcomes after matched unrelated donor versus identical sibling hematopoietic cell transplantation in adults with acute myelogenous leukemia. Blood 2012, 119:3908-3916.
21. Pidala J., Lee S.J., Ahn K.W., et al. Nonpermissive HLA-DPB1 mismatch increases mortality after myeloablative unrelated allogeneic hematopoietic cell transplantation. Blood 2014, 124:2596-2606.
22. Ciurea S.O., Zhang M.J., Bacigalupo A.A., et al. Haploidentical transplant with post-transplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. Blood 2015, 126:1033-1040.
23. Di Stasi A., Milton D.R., Poon L.M., et al. Similar transplantation outcomes for acute myeloid leukemia and myelodysplastic syndrome patients with haploidentical versus 10/10 human leukocyte antigen-matched unrelated and related donors. Biol Blood Marrow Transplant 2014, 20:1975-1981.